

Southern California Psychiatric Society  
**Psychopharmacology  
Update 29**

Saturday, January 27, 2018  
The Olympic Collection

Please Print

Name: \_\_\_\_\_

Address: \_\_\_\_\_

City/State/Zip: \_\_\_\_\_

Email: \_\_\_\_\_

		# Attending
SCPS Member	\$200	_____
Non-SCPS Member	\$225	_____
SCPS Resident *	\$30	_____
Non-SCPS Resident *	\$40	_____

Total enclosed: \$ \_\_\_\_\_

Above fees effective until 1/15/18.  
All registrations after 1/15/18 and at-door  
registrations are an additional \$25.

*\*Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. with registration form. NO EXCEPTIONS.*

**Please make check payable to SCPS and mail w/  
this registration form to: SCPS, 2999 Overland Av.,  
#208, Los Angeles, CA 90064.**

**You may also pay online at our Website via Paypal  
Go to: [socalpsych.org/psychopharmacology-  
registration.html](http://socalpsych.org/psychopharmacology-registration.html) to register online.**

**Cancellations must be received 48 hours prior to  
the meeting and will be assessed a \$45 adminis-  
trative processing fee.**

Southern California Psychiatric Society  
2999 Overland Avenue, Suite 208  
Los Angeles, CA 90064

Psychopharmacology Update 29

Saturday, January 27, 2018

SCPS presents

# Psychopharmacology Update 29

Saturday, January 27, 2018

The Olympic Collection  
11301 W. Olympic Blvd.  
Los Angeles, Ca 90064

For psychiatrists and all physicians interested in psychopharmacology



# Psychopharmacology Update 29

8:15 a.m. - Registration, Continental Breakfast, Booth Exhibits

8:55 a.m. - Opening Remarks

9:00 a.m. - An Update on Cannabis

*Joseph M. Pierre, M.D., Acting Chief, Hospital Psychiatry Division, WLA VA; Associate Director of Residency Education, UCLA Semel Institute and WLA VA; Health Sciences Clinical Professor, Department of Psychiatry, UCLA.*

In California, cannabis is now legal for both medical and recreational use. Accordingly, an increasing number of patients under clinical care may disclose cannabis use and/or inquire about its risks and benefits for mental health. This talk will review existing evidence on the potential of cannabis and cannabinoids to both help and harm patients with psychiatric disorders. Particular attention will be devoted to how the increasing delta-9-tetrahydrocannabinol (THC) potency of cannabis might be cause for concern.

10:15 a.m. - Break

10:30 a.m. - Basic Neuroscience of Neurotransmitter Neural Networks: Using the Serotonin Network as an Example of How One Neurotransmitter Can Rule Them All

*Stephen Stahl, M.D., Professor of Psychiatry, UCSD; Honorary Fellow Cambridge University (UK); Director of Psychopharmacology and Senior Academic Advisor, CA DSH; Editor-in-Chief, CNS Spectrums.*

Dr. Stahl will present the serotonin network, its neuroanatomy and its distribution of circuits and receptors within circuits to show how one neurotransmitter can have amazing regulatory properties all across the brain. This will provide an example of the neuroscience of brain circuits, and functions of receptor subtypes that can apply to each neurotransmitter system.

11:45 a.m. - Lunch Break (lunch on our own)

1:00 p.m. - Ketamine and the Treatment of Psychiatric Disorders

*Scott Fears, M.D., Ph.D., Associate Professor Clinical Health Sciences, Division Chief, Subspecialty Mental Health Clinics, Greater LA VA, Semel Institute, UCLA.*

Ketamine, first approved as an anesthetic in 1970 and later adopted by recreational drug users, has emerged over the past decade as a novel treatment for depressive symptoms in major depressive disorder and bipolar disorder. This talk will present the clinical evidence supporting ketamine's use in the treatment of psychiatric disorders with a focus on the short and long term safety profile of the drug. An overview of the emerging understanding of ketamine's action at the level of receptors and neural circuits will be provided. The talk will conclude with a discussion of how ketamine treatment might be incorporated into standard psychiatric practice.

2:15 p.m. - New Pharmacological and Psychosocial Approaches for Psychosis and Tardive Dyskinesia

*Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry; Vice Chair for Education, Semel Institute for Neuroscience at UCLA; Director, Desert Pacific Mental Illness Research, Education, and Clinical Center.*

This talk will focus on a number of new interventions for psychotic illnesses that have recently become available to clinicians. For pharmacological interventions this will include recently introduced antipsychotic medications, medications for tardive dyskinesia, and long-acting formulations of antipsychotics. Psychosocial interventions will include cognitive interventions for hallucinations and delusions; programs for first episode patients; cognitive remediation; and promising strategies for improving social cognition and negative symptoms.

Please Call (310) 815-3650 for any Questions or Concerns.

SCPS would like to thank: *Michael Gales, M.D. (Program Chair), David Fogelson, M.D., Maria Lymberis, M.D., Samuel Miles, M.D., and Heather Silverman, M.D.* for planning this event

## Overview

Once again, SCPS is honored to present a distinguished panel of experts to address topics of relevance and clinical importance for psychiatrists. The program begins with an update on existing evidence on the potential of cannabis to both help and harm patients with psychiatric disorders. We follow with a special presentation addressing the basic neuroscience of neurotransmitter neural networks, highlighting the serotonin network as a model. Following lunch we will hear about ketamine as a potential new treatment for depressive symptoms in major depression and bipolar depression. The program concludes with an update on new pharmacological and psychosocial approaches for psychosis and tardive dyskinesia.

## Objectives

At the end of this seminar, participants will have:

- 1) An enhanced evidence based understanding of the potential benefits and risks of cannabis for patients with psychiatric disorders.
- 2) Knowledge of the latest theories pertaining to the basic neuroscience of neurotransmitter neural networks, drawing on the serotonin network.
- 3) Understanding of the latest evidence based thinking regarding the use of ketamine in the treatment of major depression and bipolar depression.
- 4) Applicable knowledge regarding new pharmacological and psychosocial approaches for psychosis and tardive dyskinesias.

## Continuing Education

The Southern California Psychiatric Society is accredited by the Institute for Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. The Southern California Psychiatric Society takes responsibility for the content, quality and scientific integrity of this CME activity.

The Southern California Psychiatric Society designates this educational activity for a maximum of 5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

